Overview

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

Status:
Not yet recruiting
Trial end date:
2026-05-15
Target enrollment:
Participant gender:
Summary
This research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer. The names of the study drugs involved in this study are: - Lenvatinib - Pembrolizumab
Phase:
Phase 2
Details
Lead Sponsor:
Elizabeth K. Lee MD
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Lenvatinib
Pembrolizumab